Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
Friday, January 12, 2018 1:19:03 PM
Yes, prurisol is the least favorite of mine in IPIX pipeline. But if it ever gets approved it has its own unique charms, besides being an oral drug.
1. Not immunosuppressant
2. Presumably low manufacturing cost
One month of abacavir 600 mg daily has gone below 500 USD, Otezla is around 3000 to 4000 USD montly.
As to big pharma investing based P2a data. Some even prefer to do it then - because of the risk discounted price they can get. Novartis went public not so long time ago saying they see prices for late stage developmental drugs as too high and therefore prefer to go after riskier but cheaper earlier stage drugs.
It seems that my percentages, delightfully, do annoy you. Well, in that case, I can't resist but put few more here. These are from Otezla Esteem 1 and 2 (you know, those pivotal trials) and may help explain why I am optimistic even with prurisol.
Esteem 1, percentages for 2+ point drop in sPGA/IGA
Otezla 30 mg ITT = 526; 21.7 %
placebo ITT = 282, 3.7 %
Esteem 2, percentages for 2+ point drop in sPGA/IGA
Otezla 30 mg ITT = 274; 20.4 %
placebo ITT = 137, 4.4 %
Is it only stupid me, or does it look like prurisol percentages from that little trial can go down a lot in P3 trial and prurisol still eats Otezlas lunch?
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM